Parameter
| Biomarker | miR-371a-3p | Full name | microRNA-371a-3p | Molecular Type | Nucleic acid RNA |
|---|---|---|---|---|---|
| Molecular Formula | / | Molecular Weight | / | Core Functional Dimensions | Diagnosis, efficacy monitoring, recurrence warning, and residual lesion assessment |
| Disease | TGCT | Disease Subtypes | / | ||
| Organ | Testis | Test Sample / Technology Platform | Serum and plasma (RT-qPCR, ddPCR) | ||
| Pathobiological Mechanisms | It is derived from embryonic stem cells,highly expressed in malignant GCT and involved in maintaining cell pluripotency; its serum level is positively correlated with tumor load. | ||||
| Clinical Availability Status | Stage of research/Close to clinical (with CE-certified commercial kits available) | ||||
| Notes and Dynamics | Its sensitivity (≈90%) and specificity (>90%) far exceed those of traditional biomarkers. It is not expressed in teratomas. Multiple large-scale prospective studies are currently underway to validate its role in prognostic prediction and treatment decision guidance. | ||||